08:03 AM EDT, 10/16/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee recommended Accord Healthcare's Fovlussea drug for marketing authorization, according to a Friday notice. The drug is intended to treat several eye conditions in adults, such as wet age-related macular degeneration, proliferative diabetic retinopathy, and visual impairment due to diabetic macular edema, choroidal neovascularisation, and macular edema secondary to retinal vein occlusion. The regulator issued a positive opinion based on data showing that Fovlussea is comparable in quality, safety, and efficacy to reference drug Lucentis. The drug remains subject to final approval by the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.